Reviewer's report
Title:Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical
outcomes of gastric cancer patients treated with platinum/5-Fu-based
chemotherapy: a systematic review
Version: 1Date:5 June 2012
Reviewer: Katja Ott
Reviewer's report:
It is a relevant metaanalysis on an important topic. Many papers on different
patient cohorts treated neoadjuvatly, palliatively were recently published. This
metaanalyis tries to find relevant polymorphisms being associated with toxicity,
reponse and/or prognosis of the patients.
Major compulsory revision
Introduction:
Please delete the epidemiology and focus on your aims of your study
Add nowadays standards in neoadjuvant, perioperative and adjuvant
chemotherapy and highlight the possible associations with the respective
polymorphisms
Explain, why those polymorphisms were chosen
Results:
Please add to your subgroup analysis, the type of treatment:
Preoperative versus adjuvant versus palliative
Would it be possible to define more predictive combinations of genotypes by this
metaanalysis for response and/or prognosis?
Discussion:
Shorten please the first part-it repeats facts of the introduction and focus on your
results in combinations with literature
Address the problem of polychemotherapy: never single agents are delivered.
It`s always a combination of 5-Fu and platinum containing combinations
Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: Yes, but I do not feel adequately qualified to assess the
statistics.
Declaration of competing interests:
I have no competing interests
Katja Ott
Reviewer's report
Title:Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical
outcomes of gastric cancer patients treated with platinum/5-Fu-based
chemotherapy: a systematic review
Version: 1Date:5 June 2012
Reviewer: Katja Ott
Reviewer's report:
It is a relevant metaanalysis on an important topic. Many papers on different
patient cohorts treated neoadjuvatly, palliatively were recently published. This
metaanalyis tries to find relevant polymorphisms being associated with toxicity,
reponse and/or prognosis of the patients.
Major compulsory revision
Introduction:
Please delete the epidemiology and focus on your aims of your study
Add nowadays standards in neoadjuvant, perioperative and adjuvant
chemotherapy and highlight the possible associations with the respective
polymorphisms
Explain, why those polymorphisms were chosen
Results:
Please add to your subgroup analysis, the type of treatment:
Preoperative versus adjuvant versus palliative
Would it be possible to define more predictive combinations of genotypes by this
metaanalysis for response and/or prognosis?
Discussion:
Shorten please the first part-it repeats facts of the introduction and focus on your
results in combinations with literature
Address the problem of polychemotherapy: never single agents are delivered.
It`s always a combination of 5-Fu and platinum containing combinations
Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: Yes, but I do not feel adequately qualified to assess the
statistics.
Declaration of competing interests:
I have no competing interests
Katja Ott
Please review this paper.
user
Reviewer's report
Title:Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical
outcomes of gastric cancer patients treated with platinum/5-Fu-based
chemotherapy: a systematic review
Version: 1Date:5 June 2012
Reviewer: Katja Ott
Reviewer's report:
It is a relevant metaanalysis on an important topic. Many papers on different
patient cohorts treated neoadjuvatly, palliatively were recently published. This
metaanalyis tries to find relevant polymorphisms being associated with toxicity,
reponse and/or prognosis of the patients.
Major compulsory revision
Introduction:
Please delete the epidemiology and focus on your aims of your study
Add nowadays standards in neoadjuvant, perioperative and adjuvant
chemotherapy and highlight the possible associations with the respective
polymorphisms
Explain, why those polymorphisms were chosen
Results:
Please add to your subgroup analysis, the type of treatment:
Preoperative versus adjuvant versus palliative
Would it be possible to define more predictive combinations of genotypes by this
metaanalysis for response and/or prognosis?
Discussion:
Shorten please the first part-it repeats facts of the introduction and focus on your
results in combinations with literature
Address the problem of polychemotherapy: never single agents are delivered.
It`s always a combination of 5-Fu and platinum containing combinations
Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: Yes, but I do not feel adequately qualified to assess the
statistics.
Declaration of competing interests:
I have no competing interests
Katja Ott
assistant